Efficacy of Empagliflozin Versus Placebo in Patients With Recent Acute Myocardial Infarction: A Systematic Review
Abstract
Empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2), is well-established for managing various cardio-renal conditions, but its effectiveness in patients recovering from acute myocardial infarction (AMI) remains unclear. This systematic review aims to evaluate whether empagliflozin reduces mortality and hospitalization rates compared to placebo in this population. We identified five randomized controlled trials (RCTs) from PubMed and ScienceDirect up to May 2024, which compared empagliflozin to placebo in patients with recent AMI. A total of 7229 participants were included. The primary outcomes were reductions in mortality and hospitalization rates, while secondary outcomes included changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and left ventricular ejection fraction (LVEF). Empagliflozin did not significantly reduce cardiovascular mortality or hospitalization rates. However, some studies reported a statistically significant reduction in NT-proBNP levels of up to 15% in the empagliflozin group. Additionally, a 1.5% greater increase in LVEF was observed in patients treated with empagliflozin compared to placebo in certain studies. Although empagliflozin has a favorable safety profile and shows positive effects on biomarkers related to heart failure (HF), current evidence does not support its use as an effective intervention for reducing mortality or hospitalizations in AMI patients. Further research is needed to confirm its efficacy in…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 7,229 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.